SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Facilities

News headlines

OSE Immunotherapeutics halts recruitment in cancer vaccine trial

27-Jun-2017 - OSE Immunotherapeutics SA has halted recruitment in a Phase III trial of its cancer vaccine Tedopi (OSE2101). 

US FDA rejects Pfizer's Epogen biosimilar citing McPherson site warning

23-Jun-2017 - Concerns about Pfizer’s fill/finish plant in McPherson, Kansas have prompted the US FDA to reject the firm’s biosimilar version of Amgen’s anaemia drug Epogen.

Takeda prepping to take over EU production of stem cell therapy from 2021

23-Jun-2017 - Takeda says it is assessing manufacturing options ahead of potential European approval later this year of the Crohn’s disease stem cell therapy licensed from TiGenix.

Brazilian plant to make Humira biosimilar in 'tobacco-based bioreactors'

21-Jun-2017 - A tobacco plant-based platform could make monoclonal antibodies up to 90% cheaper than mammalian systems, says Axis Biotec which is building a pilot plant in Brazil.

Cell Medica buys T cell receptor cancer candidate from UK Catapult

20-Jun-2017 - Cell Medica says it will work with the Cell and Gene Therapy Catapult to assess automation and processing technologies involved in scaling-up the acquired cancer candidate.

Wuxi Biologics IPO in Hong Kong brings in $511m

16-Jun-2017 - Wuxi Biologics (Cayman) Inc. completed a successful IPO on the Hong Kong stock exchange on Tuesday, raising $511m.

Sanofi outlines €600m biologics manufacturing investment plan

16-Jun-2017 - Sanofi has said it will spend €600m ($673m) to increase capacity to make biologic drugs over the next three years.

Update - BioMarin to hire 50 people at Shanbally

US FDA clears BioMarin to make $380,000-a year Vimizim in Ireland

12-Jun-2017 - The US FDA has cleared BioMarin Pharmaceutical Inc. to make the enzyme replacement drug Vimizim (elosulfase alfa) at its plant in Cork, Ireland.

Lonza plugs EU cell and gene therapy manufacturing gap through PharmaCell buy

09-Jun-2017 - The acquisition of Dutch commercial cell and gene therapy maker PharmaCell places Lonza as the leading CDMO in the space, the firm says.

Takeda breaks ground on $45m Ninlaro plant in Ireland

06-Jun-2017 - Takeda has begun construction of an Irish facility to support production of its orally delivered blood cancer peptide Ninlaro (ixazomib).

Merck & Co. €280m spend in latest commitment to Irish biomanufacturing

31-May-2017 - Global demand for its biologics and vaccines has driven expansion plans and 300 jobs across two Irish facilities says MSD.

PPD expands Virginia vaccine lab with an eye on assays

24-May-2017 - Pharmaceutical Product Development LLC (PPD) has expanded its vaccine research services lab in Richmond, Virginia.

JSR Corporation invests $30m in CDMO facilities

24-May-2017 - JSR Corporation subsidiary KBI Biopharma is expanding its facilities in Durham, North Carolina and Boulder, Colorado, US, to respond to client needs.

GE looks to single-use modular BioParks to relieve capacity investment risk

23-May-2017 - Incorporating single-use and modular facilities into a vendor run bio-campus could reduce CAPEX spend dilemmas faced by drugmakers says GE Healthcare.

Amgen: Bioprocess intensification and integration key for next-generation manufacturing

23-May-2017 - Its new Singapore single-use plant is a fraction of the size of a conventional commercial facility but next-generation biomanufacturing at Amgen points to even smaller, more integrated sites.

Dr Reddy’s turns to single-use for biosimilar production in India

19-May-2017 - Dr Reddy’s will expand its biosimilar manufacturing capacity in Hyderabad by 4,000L using GE Healthcare’s FlexFactory platform based on single-use technologies.

Therachon hires Catalent to make protein dwarfism drug for Ph I trial

19-May-2017 - Therachon AG has contracted Catalent Biologics to manufacture a candidate protein therapeutic for a rare form of dwarfism.

Novartis in Switzerland: Biologics job boost but 500 'traditional' jobs to go

19-May-2017 - Novartis will add around 350 Swiss jobs to support its innovative biologics pipeline as it looks to cut 500 more “traditional” development and manufacturing roles.

Thermo Fisher: $7.2bn Patheon sits in sweet spot for bioproduction business

17-May-2017 - Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.

Single-use making its mark in India as Stelis teams with MilliporeSigma

16-May-2017 - Stelis Biopharma has partnered with Germany’s Merck on a bioprocessing services centre in Bangalore and says single-use systems could kickstart India’s biomanufacturing sector.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...

Product Innovation